Home Healthcare Biotechnology Pediatric Cancer Biomarkers Market

Pediatric Cancer Biomarkers Market Size, Share & Trends Analysis Report By Indication (Lymphoma, Neuroblastoma, Leukemia, CNS Tumors, Others), By Biomarker (Neuron-Specific enolase (NSE), Alpha-Fetoprotien (AFP), ALK (Anaplastic lymphoma receptor tyrosine kinase gene), CD19, CD20, CD22, Others), By End-User (Hospitals, Oncology Centers, Research Institutions, Diagnostic Laboratories) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Mitiksha Koul | Format: | Report Code: SR6516DR | Pages: 110
Overview TOC Segmentation Methodology
Download Free Sample

Table Of Content

  1. Executive Summary
  2. Research Scope & Segmentation
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
  3. Market Opportunity Assessment
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
  4. Market Trends
    1. Drivers
    2. Market Warning Factors
    3. Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
  5. Market Assessment
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
  6. Pediatric Cancer Biomarkers Market Size Analysis
    1. Introduction
    2. Pediatric Cancer Biomarkers Market Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
      1. Lymphoma
      2. Neuroblastoma
      3. Leukemia
      4. CNS Tumors
      5. Others
    3. Pediatric Cancer Biomarkers Market Market Size & Forecast By Biomarker 2022-2034 (USD MILLION/ Units)
      1. Neuron-Specific enolase (NSE)
      2. Alpha-Fetoprotien (AFP)
      3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
      4. CD19, CD20, CD22
      5. Others
    4. Pediatric Cancer Biomarkers Market Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
      1. Hospitals
      2. Oncology Centers
      3. Research Institutions
      4. Diagnostic Laboratories
  7. North America Pediatric Cancer Biomarkers Market Size Analysis
    1. Introduction
    2. Pediatric Cancer Biomarkers Market Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
      1. Lymphoma
      2. Neuroblastoma
      3. Leukemia
      4. CNS Tumors
      5. Others
    3. Pediatric Cancer Biomarkers Market Market Size & Forecast By Biomarker 2022-2034 (USD MILLION/ Units)
      1. Neuron-Specific enolase (NSE)
      2. Alpha-Fetoprotien (AFP)
      3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
      4. CD19, CD20, CD22
      5. Others
    4. Pediatric Cancer Biomarkers Market Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
      1. Hospitals
      2. Oncology Centers
      3. Research Institutions
      4. Diagnostic Laboratories
    5. U.S.
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
      3. Market Size & Forecast By Biomarker 2022-2034 (USD MILLION/ Units)
        1. Neuron-Specific enolase (NSE)
        2. Alpha-Fetoprotien (AFP)
        3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        4. CD19, CD20, CD22
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Research Institutions
        4. Diagnostic Laboratories
    6. Canada
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
      3. Market Size & Forecast By Biomarker 2022-2034 (USD MILLION/ Units)
        1. Neuron-Specific enolase (NSE)
        2. Alpha-Fetoprotien (AFP)
        3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        4. CD19, CD20, CD22
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Research Institutions
        4. Diagnostic Laboratories
  8. Europe Pediatric Cancer Biomarkers Market Size Analysis
    1. Introduction
    2. Pediatric Cancer Biomarkers Market Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
      1. Lymphoma
      2. Neuroblastoma
      3. Leukemia
      4. CNS Tumors
      5. Others
    3. Pediatric Cancer Biomarkers Market Market Size & Forecast By Biomarker 2022-2034 (USD MILLION/ Units)
      1. Neuron-Specific enolase (NSE)
      2. Alpha-Fetoprotien (AFP)
      3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
      4. CD19, CD20, CD22
      5. Others
    4. Pediatric Cancer Biomarkers Market Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
      1. Hospitals
      2. Oncology Centers
      3. Research Institutions
      4. Diagnostic Laboratories
    5. U.K.
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
      3. Market Size & Forecast By Biomarker 2022-2034 (USD MILLION/ Units)
        1. Neuron-Specific enolase (NSE)
        2. Alpha-Fetoprotien (AFP)
        3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        4. CD19, CD20, CD22
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Research Institutions
        4. Diagnostic Laboratories
    6. Germany
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
      3. Market Size & Forecast By Biomarker 2022-2034 (USD MILLION/ Units)
        1. Neuron-Specific enolase (NSE)
        2. Alpha-Fetoprotien (AFP)
        3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        4. CD19, CD20, CD22
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Research Institutions
        4. Diagnostic Laboratories
    7. France
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
      3. Market Size & Forecast By Biomarker 2022-2034 (USD MILLION/ Units)
        1. Neuron-Specific enolase (NSE)
        2. Alpha-Fetoprotien (AFP)
        3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        4. CD19, CD20, CD22
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Research Institutions
        4. Diagnostic Laboratories
    8. Spain
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
      3. Market Size & Forecast By Biomarker 2022-2034 (USD MILLION/ Units)
        1. Neuron-Specific enolase (NSE)
        2. Alpha-Fetoprotien (AFP)
        3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        4. CD19, CD20, CD22
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Research Institutions
        4. Diagnostic Laboratories
    9. Italy
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
      3. Market Size & Forecast By Biomarker 2022-2034 (USD MILLION/ Units)
        1. Neuron-Specific enolase (NSE)
        2. Alpha-Fetoprotien (AFP)
        3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        4. CD19, CD20, CD22
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Research Institutions
        4. Diagnostic Laboratories
    10. Russia
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
      3. Market Size & Forecast By Biomarker 2022-2034 (USD MILLION/ Units)
        1. Neuron-Specific enolase (NSE)
        2. Alpha-Fetoprotien (AFP)
        3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        4. CD19, CD20, CD22
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Research Institutions
        4. Diagnostic Laboratories
    11. Nordic
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
      3. Market Size & Forecast By Biomarker 2022-2034 (USD MILLION/ Units)
        1. Neuron-Specific enolase (NSE)
        2. Alpha-Fetoprotien (AFP)
        3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        4. CD19, CD20, CD22
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Research Institutions
        4. Diagnostic Laboratories
    12. Benelux
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
      3. Market Size & Forecast By Biomarker 2022-2034 (USD MILLION/ Units)
        1. Neuron-Specific enolase (NSE)
        2. Alpha-Fetoprotien (AFP)
        3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        4. CD19, CD20, CD22
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Research Institutions
        4. Diagnostic Laboratories
    13. Rest of Europe
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
      3. Market Size & Forecast By Biomarker 2022-2034 (USD MILLION/ Units)
        1. Neuron-Specific enolase (NSE)
        2. Alpha-Fetoprotien (AFP)
        3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        4. CD19, CD20, CD22
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Research Institutions
        4. Diagnostic Laboratories
  9. APAC Pediatric Cancer Biomarkers Market Size Analysis
    1. Introduction
    2. Pediatric Cancer Biomarkers Market Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
      1. Lymphoma
      2. Neuroblastoma
      3. Leukemia
      4. CNS Tumors
      5. Others
    3. Pediatric Cancer Biomarkers Market Market Size & Forecast By Biomarker 2022-2034 (USD MILLION/ Units)
      1. Neuron-Specific enolase (NSE)
      2. Alpha-Fetoprotien (AFP)
      3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
      4. CD19, CD20, CD22
      5. Others
    4. Pediatric Cancer Biomarkers Market Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
      1. Hospitals
      2. Oncology Centers
      3. Research Institutions
      4. Diagnostic Laboratories
    5. China
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
      3. Market Size & Forecast By Biomarker 2022-2034 (USD MILLION/ Units)
        1. Neuron-Specific enolase (NSE)
        2. Alpha-Fetoprotien (AFP)
        3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        4. CD19, CD20, CD22
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Research Institutions
        4. Diagnostic Laboratories
    6. Korea
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
      3. Market Size & Forecast By Biomarker 2022-2034 (USD MILLION/ Units)
        1. Neuron-Specific enolase (NSE)
        2. Alpha-Fetoprotien (AFP)
        3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        4. CD19, CD20, CD22
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Research Institutions
        4. Diagnostic Laboratories
    7. Japan
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
      3. Market Size & Forecast By Biomarker 2022-2034 (USD MILLION/ Units)
        1. Neuron-Specific enolase (NSE)
        2. Alpha-Fetoprotien (AFP)
        3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        4. CD19, CD20, CD22
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Research Institutions
        4. Diagnostic Laboratories
    8. India
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
      3. Market Size & Forecast By Biomarker 2022-2034 (USD MILLION/ Units)
        1. Neuron-Specific enolase (NSE)
        2. Alpha-Fetoprotien (AFP)
        3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        4. CD19, CD20, CD22
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Research Institutions
        4. Diagnostic Laboratories
    9. Australia
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
      3. Market Size & Forecast By Biomarker 2022-2034 (USD MILLION/ Units)
        1. Neuron-Specific enolase (NSE)
        2. Alpha-Fetoprotien (AFP)
        3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        4. CD19, CD20, CD22
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Research Institutions
        4. Diagnostic Laboratories
    10. Taiwan
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
      3. Market Size & Forecast By Biomarker 2022-2034 (USD MILLION/ Units)
        1. Neuron-Specific enolase (NSE)
        2. Alpha-Fetoprotien (AFP)
        3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        4. CD19, CD20, CD22
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Research Institutions
        4. Diagnostic Laboratories
    11. South East Asia
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
      3. Market Size & Forecast By Biomarker 2022-2034 (USD MILLION/ Units)
        1. Neuron-Specific enolase (NSE)
        2. Alpha-Fetoprotien (AFP)
        3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        4. CD19, CD20, CD22
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Research Institutions
        4. Diagnostic Laboratories
    12. Rest of Asia-Pacific
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
      3. Market Size & Forecast By Biomarker 2022-2034 (USD MILLION/ Units)
        1. Neuron-Specific enolase (NSE)
        2. Alpha-Fetoprotien (AFP)
        3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        4. CD19, CD20, CD22
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Research Institutions
        4. Diagnostic Laboratories
  10. Middle East and Africa Pediatric Cancer Biomarkers Market Size Analysis
    1. Introduction
    2. Pediatric Cancer Biomarkers Market Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
      1. Lymphoma
      2. Neuroblastoma
      3. Leukemia
      4. CNS Tumors
      5. Others
    3. Pediatric Cancer Biomarkers Market Market Size & Forecast By Biomarker 2022-2034 (USD MILLION/ Units)
      1. Neuron-Specific enolase (NSE)
      2. Alpha-Fetoprotien (AFP)
      3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
      4. CD19, CD20, CD22
      5. Others
    4. Pediatric Cancer Biomarkers Market Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
      1. Hospitals
      2. Oncology Centers
      3. Research Institutions
      4. Diagnostic Laboratories
    5. UAE
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
      3. Market Size & Forecast By Biomarker 2022-2034 (USD MILLION/ Units)
        1. Neuron-Specific enolase (NSE)
        2. Alpha-Fetoprotien (AFP)
        3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        4. CD19, CD20, CD22
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Research Institutions
        4. Diagnostic Laboratories
    6. Turkey
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
      3. Market Size & Forecast By Biomarker 2022-2034 (USD MILLION/ Units)
        1. Neuron-Specific enolase (NSE)
        2. Alpha-Fetoprotien (AFP)
        3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        4. CD19, CD20, CD22
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Research Institutions
        4. Diagnostic Laboratories
    7. Saudi Arabia
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
      3. Market Size & Forecast By Biomarker 2022-2034 (USD MILLION/ Units)
        1. Neuron-Specific enolase (NSE)
        2. Alpha-Fetoprotien (AFP)
        3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        4. CD19, CD20, CD22
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Research Institutions
        4. Diagnostic Laboratories
    8. South Africa
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
      3. Market Size & Forecast By Biomarker 2022-2034 (USD MILLION/ Units)
        1. Neuron-Specific enolase (NSE)
        2. Alpha-Fetoprotien (AFP)
        3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        4. CD19, CD20, CD22
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Research Institutions
        4. Diagnostic Laboratories
    9. Egypt
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
      3. Market Size & Forecast By Biomarker 2022-2034 (USD MILLION/ Units)
        1. Neuron-Specific enolase (NSE)
        2. Alpha-Fetoprotien (AFP)
        3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        4. CD19, CD20, CD22
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Research Institutions
        4. Diagnostic Laboratories
    10. Nigeria
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
      3. Market Size & Forecast By Biomarker 2022-2034 (USD MILLION/ Units)
        1. Neuron-Specific enolase (NSE)
        2. Alpha-Fetoprotien (AFP)
        3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        4. CD19, CD20, CD22
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Research Institutions
        4. Diagnostic Laboratories
    11. Rest of MEA
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
      3. Market Size & Forecast By Biomarker 2022-2034 (USD MILLION/ Units)
        1. Neuron-Specific enolase (NSE)
        2. Alpha-Fetoprotien (AFP)
        3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        4. CD19, CD20, CD22
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Research Institutions
        4. Diagnostic Laboratories
  11. LATAM Pediatric Cancer Biomarkers Market Size Analysis
    1. Introduction
    2. Pediatric Cancer Biomarkers Market Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
      1. Lymphoma
      2. Neuroblastoma
      3. Leukemia
      4. CNS Tumors
      5. Others
    3. Pediatric Cancer Biomarkers Market Market Size & Forecast By Biomarker 2022-2034 (USD MILLION/ Units)
      1. Neuron-Specific enolase (NSE)
      2. Alpha-Fetoprotien (AFP)
      3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
      4. CD19, CD20, CD22
      5. Others
    4. Pediatric Cancer Biomarkers Market Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
      1. Hospitals
      2. Oncology Centers
      3. Research Institutions
      4. Diagnostic Laboratories
    5. Brazil
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
      3. Market Size & Forecast By Biomarker 2022-2034 (USD MILLION/ Units)
        1. Neuron-Specific enolase (NSE)
        2. Alpha-Fetoprotien (AFP)
        3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        4. CD19, CD20, CD22
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Research Institutions
        4. Diagnostic Laboratories
    6. Mexico
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
      3. Market Size & Forecast By Biomarker 2022-2034 (USD MILLION/ Units)
        1. Neuron-Specific enolase (NSE)
        2. Alpha-Fetoprotien (AFP)
        3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        4. CD19, CD20, CD22
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Research Institutions
        4. Diagnostic Laboratories
    7. Argentina
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
      3. Market Size & Forecast By Biomarker 2022-2034 (USD MILLION/ Units)
        1. Neuron-Specific enolase (NSE)
        2. Alpha-Fetoprotien (AFP)
        3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        4. CD19, CD20, CD22
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Research Institutions
        4. Diagnostic Laboratories
    8. Chile
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
      3. Market Size & Forecast By Biomarker 2022-2034 (USD MILLION/ Units)
        1. Neuron-Specific enolase (NSE)
        2. Alpha-Fetoprotien (AFP)
        3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        4. CD19, CD20, CD22
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Research Institutions
        4. Diagnostic Laboratories
    9. Colombia
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
      3. Market Size & Forecast By Biomarker 2022-2034 (USD MILLION/ Units)
        1. Neuron-Specific enolase (NSE)
        2. Alpha-Fetoprotien (AFP)
        3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        4. CD19, CD20, CD22
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Research Institutions
        4. Diagnostic Laboratories
    10. Rest of LATAM
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
      3. Market Size & Forecast By Biomarker 2022-2034 (USD MILLION/ Units)
        1. Neuron-Specific enolase (NSE)
        2. Alpha-Fetoprotien (AFP)
        3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        4. CD19, CD20, CD22
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Research Institutions
        4. Diagnostic Laboratories
  12. Competitive Landscape
    1. Pediatric Cancer Biomarkers Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    3. Tier Structure Analysis
    4. Recent Developments
  13. Market Players Assessment
    1. Abbott Laboratories.
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Agilent Technologies, Inc.
    3. Beckman Coulter, Inc.
    4. bioMérieux SA.
    5. Bio-Rad Laboratories, Inc.
    6. Hoffmann-La Roche AG.
    7. Myriad Genetics, Inc.
    8. QIAGEN N.V.
    9. Randox Laboratories Limited.
    10. RayBiotech Life, Inc.
    11. Thermo Fisher Scientific Inc.
    12. Illumina, Inc.
    13. AstraZeneca PLC.
    14. Guardant Health, Inc.
    15. ICON Public Limited Company.
    16. Merck Sharp & Dohme Corp.
  14. Research Methodology
    1. Research Data
      1. Secondary Data
        1. Major Secondary Sources
        2. Key Data from Secondary Sources
      2. Primary Data
        1. Key Data from Primary Sources
        2. Breakdown of Primaries
      3. Secondary And Primary Research
        1. Key Industry Insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
  15. Appendix
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  16. Disclaimer
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.